BioMarin

Drug may reduce SIDS in children with achondroplasia

via Murdoch Children’s Research Institute A drug that boosts bone growth in children with achondroplasia may also reduce their chances of sudden infant death syndrome (SIDS), sleep apnoea and needing…

Treatment · Vosoritide

Vosoritide therapy in children with achondroplasia aged 3−59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial

Source: The Lancet Child & Adolescent Health Authors: Prof Ravi Savarirayan, MD • Prof William R Wilcox, MD • Prof Paul Harmatz, MD • John Phillips III, MD • Lynda…

Achondroplasia · International · Vosoritide

Health Ministry announces introduction of Achondroplasia drug for children patients

SOURCE: AGENDA.GE Agenda.ge, 14 Nov 2023 – 15:18, Tbilisi,Georgia Vosoritide, a medication used for the treatment of achondroplasia among children patients, is now available in Georgia, the country’s Ministry of…

Achondroplasia · BioMarin · Hypochondroplasia · Voxzogo

U.S. Food and Drug Administration Approves BioMarin’s VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia

The following press release was obtained from BioMarin.com. To learn more about BioMarin, VOXZOGO®, vosorotide, and their other pipelines and research for achondroplasia and other skeletal dysplasias, click here. Expanded…

BioMarin · Pharmachon · Voxzogo

PHARMACHON: Pharmacokinetics of VOXZOGO

The following, written by Victoria Garcia, RN, exclusively for The Chandler Project and members of the achondroplasia community are questions and answers compiled from ‘One Family’s Story: A Guide to…

Achondroplasia · Treatment · Voxzogo

Children with achondroplasia to benefit from life-changing treatment added to PBS

The Murdoch Children’s Research Institute has welcomed the news that children born with the most common form of dwarfism, achondroplasia, will have access to a new life-changing treatment on the Pharmaceutical Benefits Scheme (PBS).